Marinomed Biotech AG
ISIN: ATMARINOMED6
WKN: A2N9MM
05 December 2024 02:34PM

EQS-Adhoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

Marinomed Biotech AG · ISIN: ATMARINOMED6 · EQS - adhoc news
Country: Austria · Primary market: Austria · EQS NID: 2045241

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase
Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

05-Dec-2024 / 14:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the “Second Capital Increase”). The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. A report on the intended exclusion of the subscription rights of existing shareholders (the “Report”) was published on the Company's website from November 28, 2024 onwards, and on the electronic announcement and information platform of the Federal Government of Austria ("EVI") on November 28, 2024. The issue price per new share is EUR 8 so that the total issue price amounts to EUR 670,000. The required Supervisory Board resolution for the Second Capital Increase under exclusion of statutory subscription rights can be passed no earlier than two weeks after publication of the Report. The Company had already provided information on a possible second capital increase in ad hoc announcements of September 2, September 15, September 18 and November 27, 2024.

All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.

+++ End of ad-hoc announcement +++

 


End of Inside Information

05-Dec-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 2045241

 
End of Announcement EQS News Service

2045241  05-Dec-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2045241&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 4,67 6,14 8,12 11,63 11,28 9,18 0,00
EBITDA1,2 -4,90 -5,88 -5,39 -3,54 -4,24 -4,45 0,00
EBITDA-Margin3 -104,93 -95,77 -66,38 -30,44 -37,59 -48,48 0,00
EBIT1,4 -5,14 -6,21 -5,82 -4,14 -4,91 -5,13 0,00
EBIT-Margin5 -110,06 -101,14 -71,68 -35,60 -43,53 -55,88 0,00
Net Profit (Loss)1 -12,10 -7,22 -6,01 -5,89 -6,40 -6,80 0,00
Net-Margin6 -259,10 -117,59 -74,02 -50,65 -56,74 -74,07 0,00
Cashflow1,7 -4,32 -7,64 -6,89 -4,87 -5,20 -4,53 0,00
Earnings per share8 -12,10 -5,10 -4,10 -4,00 -4,30 -4,50 -2,40
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: BDO

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Marinomed Biotech
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A2N9MM ATMARINOMED6 AG 25,43 Mio € 01.02.2019 Halten 8FWR88QM+8R
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
-7,15 0,00 0,00 -3,15 -2,51 -5,62 2,77
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
20.06.2024 22.05.2024 20.08.2024 21.11.2024 16.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-3,70%
14,30 €
ATH 148,00 €
+45,10% +19,90% -52,17% -53,72% -80,93%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL